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Introduction: Treatment of chronic skin wounds is difficult and largely ineffective. Little improvement has been
shown in promoting the healing of these wounds in the past few decades. Innovative treatments to enhance
chronic wound healing process are therefore needed.
Methods: In this study, we examined the efficacy of angiopoietin-1 gene-modified bone marrow mesenchymal
stem cells (Ang1-MSCs) on the promotion of cutaneous wound healing in rats. Excisional full-thickness wounds
were treated with Ang1-MSCs, a recombinant adenovirus encoding angiopoietin-1 (Ad-Ang1), unmodified bone
marrow mesenchymal stem cells (MSCs), or vehicle medium (sham).
Results: The results showed that Ang1-MSCs significantly promoted wound healing with increased epidermal and
dermal regeneration, and enhanced angiogenesis compared with MSCs, Ad-Ang1 or sham treatment. Moreover,
Ang1-MSCs expressed CD31 in the wound, suggesting a direct contribution of Ang1-MSCs to angiogenesis.
Conclusions: Here we show that Ang1-MSCs accelerate wound healing by promoting skin regeneration and
angiogenesis, compared with MSCs or Ad-Ang1 alone.Introduction
The wound-healing process involves complex biological
and molecular events including cell migration, prolifera-
tion, extracellular matrix deposition, angiogenesis, and
tissue remodeling. Angiogenesis is an essential step in
the process, and the formation of new blood vessels
ensures the delivery of oxygen, nutritional support and
growth factors. However, angiogenesis is often markedly
impaired in chronic wounds, and poor angiogenesis de-
lays wound healing. Strategies to stimulate angiogenesis
have therefore been investigated as an approach to acce-
lerating wound healing [1].
Mesenchymal stem cells (MSCs) can differentiate into
a variety of mesodermal cell lineages [2-6]. Recent stu-
dies found that MSCs significantly enhanced wound
closure and showed satisfactory effects in the treatment
of chronic wounds in humans and animals [7-18]. Fur-
ther studies demonstrated that MSCs promoted wound
healing by improving angiogenesis [19,20]. Moreover,* Correspondence: jinhaiyan200409@hotmail.com
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reproduction in any medium, provided the orsome studies reported that engrafted MSCs in the
wound exerted a paracrine effect on angiogenesis by
increasing the levels of angiogenic factors such as
angiopoietin-1 (Ang1) and vascular endothelial growth
factor [21].
Angiopoietins represent a major family of angiogenic
factors, including Ang1, which acts via the phospho-
rylation of the Tie-2 receptor [22]. The Ang1/Tie2 inte-
raction mediates maturation of neovessels into more
complex and functional vasculature [23,24]. Recent stu-
dies revealed that the application of recombinant adeno-
virus encoding angiopoietin-1 (Ad-Ang1) or Ang1 protein
accelerates wound closure, skin regeneration, and angio-
genesis in animals [25,26].
These studies showed that the application of MSCs
alone, Ad-Ang1 or Ang1 protein could accelerate wound
healing. However, MSCs alone do not produce enough
Ang1, which promotes angiogenesis, while Ad-Ang1 or
Ang1 protein alone do not provide the cells and cellular
factors needed to create the optimal wound-healing mi-
croenvironment. Ang1 gene-modified MSCs may there-
fore help to overcome these problems. Angiopoietin-1
gene-modified bone marrow mesenchymal stem cells
(Ang1-MSCs) not only continuously release Ang1 in situ,his is an Open Access article distributed under the terms of the Creative
ommons.org/licenses/by/2.0), which permits unrestricted use, distribution, and
iginal work is properly cited.
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suitable environment to lead to faster wound-healing.
We therefore compared the rate of wound healing
promoted by Ang1-MSCs, MSCs, and Ad-Ang1 in an
excisional-wound model. We implanted green fluores-
cent protein (GFP)-expressing Ang1-MSCs into exci-
sional wounds and examined their effects on skin
regeneration and angiogenesis compared with MSCs,
Ad-Ang1 or sham treatment. Our results showed that
compared with MSCs, Ad-Ang1 or sham, Ang1-MSCs
accelerate wound healing by promoting skin regener-
ation and angiogenesis.
Materials and methods
Isolation and purification of mesenchymal stem cells
Bone marrow was collected from the femurs of 5-week-
old to 7-week-old male Sprague–Dawley rats. Bone mar-
row mononuclear cells were isolated by Ficoll–Paque
density-gradient centrifugation. Nucleated cells were
plated in plastic tissue culture dishes and incubated in
Dulbecco’s modified Eagle’s medium (DMEM; Gibco,
Grand Island, NY, USA) supplemented with 10% fetal
bovine serum (Gibco) and 1% penicillin–streptomycin
solution (Sigma-Aldrich, St Louis, MO, USA) at 37°C
with 5% CO2. Confluent cells were trypsinized and
expanded.
Phenotypic characterization of mesenchymal stem cells
Cell immunophenotypes were examined by flow cyto-
metric analysis and immunofluorescence staining. For
flow cytometry, the cells were incubated at 4°C for
30 minutes with fluorescein isothiocyanate-conjugated
monoclonal antibodies against CD34, CD45, CD29, and
CD90 or control isotype IgG (all obtained from BD
Pharmingen, San Diego, CA, USA). The labeled cells
were analyzed using a flow cytometer with Cell Quest
software (Becton Dickinson, CA, USA). For immuno-
fluorescence staining, subconfluent cells were cultured
on chambered slides and were then fixed with 4% para-
formaldehyde. The samples were incubated with primary
antibodies at 4°C overnight. The primary antibodies were
detected using Cy2-conjugated or Cy3-conjugated sec-
ondary antibodies. Cell nuclei were stained with 4′,6-
diamidino-2-phenylindole (Sigma-Aldrich).
Generation of Ad-GFP-Ang1
Infectious recombinant adenovirus particles were col-
lected after homologous recombination of a shuttle vec-
tor with the pAdEasy system (Qbiogene, Carlsbad, CA,
USA) in BJ5183 cells and packaging in embryonal kidney
293 cells. Briefly, Ang1 cDNA was subcloned into the
shuttle plasmid pAdTrack-CMV. The resultant plasmid
was linearized by digestion with the restriction endo-
nuclease PmeI and then transformed into Escherichiacoli BJ5183 that had been transformed with the adeno-
viral backbone plasmid pAdEasy-1. Recombinant plas-
mids were screened with kanamycin and confirmed by
restriction endonuclease analysis (PacI). The recombin-
ant adenovirus vector was packaged and amplified in
293 cells.
Infection of mesenchymal stem cells
The MSCs were grown to 80% confluence and were then
cultured in fresh nonserum media containing the recom-
binant adenovirus. After incubation for 2 hours, the
medium was then removed and the cells were washed
with DMEM and recultured in normal medium. To
evaluate the transduction efficiency of Ad-GFP-Ang1 on
MSCs, GFP was detected by fluorescence microscopy.
Analysis of exogenous gene expression
Exogenous Ang1 gene expression in MSCs was detected
using RT-PCR and western blot analysis. For RT-PCR,
total RNA was extracted from cultured cells using
TRIzol reagent (Invitrogen, Carlsbad, CA, USA) follo-
wing the manufacturer’s instructions. Purified RNA was
then used for one-step RT-PCR (Qiagen Corporation,
Valencia, CA, USA). The Ang1 primers used were: 5′-
AAATATGAAGTCGGAGATGG-3′ and 5′-CAAAGGC
TGACAAGGTTATG-3′). Relative quantification of
target-gene expression was performed using the house-
keeping gene β-actin as an internal control.
For western blotting, cell proteins were extracted in a
lysis buffer containing 1% Triton X-100 and proteinase
inhibitors (Sigma-Aldrich). The protein concentrations
were determined using the Bradford dye-binding assay
with bovine serum albumin as the standard. Equal
amounts of the protein and prestained molecular weight
markers were separated on SDS-PAGE and transferred
onto polyvinylidene difluoride membranes. The mem-
branes were then incubated with a mAb against Ang1
(Abcam, Cambridge, MA, USA), followed by incubation
with horseradish peroxidase-conjugated secondary anti-
body. The protein bands were detected by chemilumin-
escence using an ECL kit (Perfect Biotech, Shanghai,
China).
Animals and treatment
Male rats (8 to 10 weeks old) with an average weight of
250 to 300 g were used in this study. Animal care and
experimental procedures were approved by the Animal
Care Committees of Zhejiang University. Hair was re-
moved from the dorsal surface and the animals were
anesthetized. Two 2 cm diameter full-thickness exci-
sional skin wounds were then created on each side of
the midline. The rats were then divided randomly into
the following groups: sham (treatment with an equal vol-
ume of vehicle medium, n = 10), MSCs (treatment with
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dermally at the margin of the excisional wound at four
injection sites and 0.3 × 106 in 20 μl DMEM applied
onto the wound bed, n = 10), Ad-Ang1 (treatment with
1 × 109 plaque-forming units of recombinant adenovirus
expressing Ang1, n = 10), and Ang1-MSCs (treatment
with 1 × 106 GFP+-Ang1-MSCs, 0.7 × 106 in 80 μl
DMEM injected intradermally at the margin of the exci-
sional wound at four injection sites and 0.3 × 106 in
20 μl DMEM applied onto the wound bed, n = 10).
Evaluation of wound closure
The percentage of wound closure was calculated as
follows:
ðArea of original wound − area of actual wound=
area of original woundÞ  100
The wound area was measured by tracing the wound
margin followed by calculation using an image-analysis
program. The digital analysis was carried out by investi-
gators who were blinded to group assignment.
Histochemistry and immunohistochemistry
The rats were sacrificed at 3, 7, 14, and 21 days after
the different treatments, at which time points skin
samples, including the wound and the surrounding
skin, were harvested using punch biopsy. Freshly har-
vested samples were fixed and embedded for histochem-
ical analysis. The sections were stained with hematoxylin
and eosin.
For immunohistochemical labeling, sections were in-
cubated overnight at 4°C with primary antibody, then in-
cubated with biotinylated secondary antibody, followed
by incubation with streptavidin–horseradish peroxidase.
Antibody binding sites were visualized by incubating in
a diaminobenzidene solution, and counterstained with
hematoxylin.
For Masson’s trichrome staining, the tissue sections
were deparaffinized and rehydrated, and were then stained
according to the Masson’s Trichrome Staining Kit (Yike
Biotech, Guangzhou, China) instructions. Briefly, sections
were placed in Bouin’s fixative after being deparaffinized
and rehydrated through xylene and ethanol, and stained in
Weigert’s iron hematoxylin working solution, followed by
staining in Biebrich scarlet acid fuchsin solution. The sec-
tions were then differentiated in phosphotungstic acid so-
lution and transferred directly (without rinsing) into light
green solution. After rinsing, the sections were differenti-
ated in 1% acetic acid solution, followed by dehydration in
95% ethyl alcohol and absolute ethyl alcohol. This method
allows for the collagen to be stained green.Immunostaining and confocal microscopy
Double-staining was performed to determine whether
MSCs differentiated into endothelial cells and whether
the transplanted cells expressed Ang1 in the wound. The
tissue sections were preincubated with sodium borohy-
dride to reduce autofluorescence and were then incu-
bated with a mAb against CD31 (Novus Biologicals Inc.,
Littleton, CO, USA) or Ang1, which was followed by de-
tection with a Cy3-conjugated secondary antibody. The
MSCs were tagged with GFP and therefore did not need
to be labeled for easy visualization. The nuclei were
stained with Hoechst. Confocal images were obtained
using a Zeiss LSM 510 confocal microscope (Carl Zeiss,
Jena, Germany).
Statistical analysis
Data were expressed as the mean ± standard deviation
and were analyzed by one-way analysis of variance fol-
lowed by a Bonferroni’s post-hoc test for multiple compa-
risons. P <0.05 was considered statistically significant.
Results
Characteristics of primary antibody and Ang1-MSCs
Both flattened and spindle-shaped cells were present in
culture. Ang1 gene-modified MSCs showed similar flat-
tened and spindle shapes in culture (Figure 1A). Im-
munophenotypic analysis showed that the MSCs used in
the experiment were negative for the lineage markers
CD34 and CD45, and strongly positive for the specific sur-
face antigens CD29 (95.3 ± 3.2%) and CD90 (94.9 ± 3.7%)
(Figure 1B,C), which are typical of MSCs.
Expression of exogenous angiopoietin-1 in mesenchymal
stem cells
We constructed recombinant adenovirus vectors ex-
pressing Ang1 and used them to infect MSCs. After in-
fection, 96.4 ± 2.3% of the target cells expressed GFP
(Figure 2), which is an indicator of efficient transfection.
The RT-PCR products for the expected Ang1 fragment
were detected in Ad-GFP-Ang1-MSCs (Figure 3A), but
not in unmodified MSCs or Ad-GFP-MSCs (control
adenovirus-infected MSCs). Consistent with the mRNA
expression, Ang1 protein was only present in Ang1-MSCs
(Figure 3B) and was not detected in MSCs or Ad-MSCs.
These results indicate that transgenic Ang1 was success-
fully expressed in Ang1-MSCs.
Angiopoietin-1 gene-modified bone marrow
mesenchymal stem cells enhance wound healing
Wound closure percentages in the different groups at dif-
ferent times post transplantation are shown in Figure 4.
The wound closure percentage in the Ang1-MSC-treated
rats was significantly greater than that in the other groups
at different days post transplantation, suggesting that
Figure 1 Characterization of mesenchymal stem cells. (A) Morphologies of mesenchymal stem cells (MSCs) and angiopoietin-1 gene-
modified bone marrow mesenchymal stem cells (Ang1-MSCs) in culture. (B) Immunophenotypes of MSCs in culture. (C) MSCs were analyzed
using flow cytometry.
Figure 2 Expression of green fluorescent protein in mesenchymal stem cells after angiopoietin-1 gene modification. Ang1-MSCs,
angiopoietin-1 gene-modified bone marrow mesenchymal stem cells; GFP, green fluorescent protein.
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Figure 3 Expression of exogenous angiopoietin-1 in mesenchymal stem cells. (A) RT-PCR-amplified mRNA of exogenous gene.
(B) Western blot analysis of exogenous proteins. Lane 1, unmodified mesenchymal stem cells (MSCs); lane 2, MSCs infected with control
adenovirus; lane 3, MSCs infected with recombinant adenovirus containing Ang1-MSCs. GAPDH, glyceraldehyde 3-phosphate
dehydrogenase.
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MSCs and Ad-Ang1.
Histopathological evaluations
Histological analysis over time indicated that Ang1-
MSC-treated wounds showed more stable features in the
granular and spinous layers and displayed a flatter epi-
thelium with a more clearly developed stratum corneum
(Figure 5A) compared with the other groups, indicating
a more mature epithelium. In addition, Ang1-MSC-
treated wounds appeared to have increased numbers of
skin appendages compared with other groups. More-
over, the epidermal cellularity in the Ang1-MSC-treated
wounds was significantly reduced and the epidermis was
thinner (Figure 5B) compared with the other groups. At
day 21, the epithelial thickness of the Ang1-MSC-treated
wound equaled the thickness of the surrounding un-
wounded epithelium. However, epidermal cellularity in
other-treated wounds was still higher and had a prolife-
rative epithelium at day 21, suggesting higher cellularFigure 4 Angiopoietin-1 gene-modified bone marrow
mesenchymal stem cells promote wound closure in vivo.
Angiopoietin-1 gene-modified bone marrow mesenchymal stem cell
(Ang1-MSC)-treated wounds healed faster compared with those in
the other groups. Analysis of variance versus mesenchymal stem
cells (MSCs), recombinant adenovirus encoding angiopoietin-1
(Ad-Ang1) or sham, *P <0.05.activity and prolongation of epidermal inflammation com-
pared with Ang1-MSC-treated wounds. These results in-
dicate that Ang1-MSCs accelerate epidermal regeneration.
Collagen deposition
The results of Masson’s trichrome staining showed that
Ang1-MSC-treated wounds displayed an arranged colla-
gen network and smooth collagen deposition (Figure 6A),
both of which were absent in the other groups, sugges-
ting that Ang1-MSC-treated wounds had more mature
collagen development than wounds in the other groups.
We then measured the positive collagen-staining area
relative to total area in the samples. The positive colla-
gen staining percentage in the Ang1-MSC-treated wound
was significantly greater than in the other groups at dif-
ferent days post transplantation (Figure 6B). The results
showed that treatment with Ang1-MSCs significantly in-
creased collagen deposition, resulting in much denser col-
lagen than in any other treatment group, especially at day
21 after treatment.
Engraftment of Ang1-MSCs into the wound skin
Engraftment of Ang1-MSCs into the wound skin was
detected by labeling gene-modified MSCs with GFP and
observing them under a fluorescence microscope. Nu-
merous GFP+ MSCs were found closely associated with
host cells in Ang1-MSC-treated wounds at day 7, and
GFP+ MSCs were seen in the epidermal and dermal
components throughout the healing process even at day
21 after transplantation (Figure 7A). Cells of coexpres-
sing GFP and Ang1 were detected in the wounds treated
with Ang1-MSCs (Figure 7B) up to day 21 post treat-
ment. These results indicate that topically applied Ang1-
MSCs migrated into the wound, integrated into the
neoepidermis and neodermis, and continually expressed
Ang1.
Angiopoietin-1 gene-modified bone marrow
mesenchymal stem cells enhance angiogenesis
We performed immunostaining using a specific antibody
for the blood vessel endothelial cell marker CD31. As
shown in Figure 8A, the proportion of CD31-positive
Figure 5 Histological analysis of wound and epidermal thickness. (A) Angiopoietin-1 gene-modified bone marrow mesenchymal stem cell
(Ang1-MSC)-treated wounds showed more stable features in the granular and spinous layers, and the epidermal layer was more mature.
Completely developed epidermis with regenerated skin appendages (arrows) is observed at day 21 after Ang1-MSC treatment of the wound.
Scale bar = 50 μm. (B) Wounds treated with Ang1-MSCs displayed thinner epidermis compared with wounds treated in the other groups.
Analysis of variance versus mesenchymal stem cells (MSCs), recombinant adenovirus encoding angiopoietin-1 (Ad-Ang1) or sham, *P <0.05.
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wounds compared with Ad-Ang1-treated, MSC-treated
or sham-treated wounds. In addition, we measured over-
all blood vessel density (CD31-immunopositive areas/
total areas) in the wound margin. The results showed
the overall capillary density in the margin of Ang1-
MSC-treated wounds was significantly higher than in
that of the Ad-Ang1-treated, MSC-treated, or sham-
treated wounds (Figure 8B). Moreover, to investigateFigure 6 Masson’s trichrome staining for collagen. (A) Representative t
gene-modified bone marrow mesenchymal stem cell (Ang1-MSC)-treated w
mature collagen development than in the other groups. Scale bar = 50 μm
wounds in the other groups. Analysis of variance versus mesenchymal stem
(Ad-Ang1) or sham, *P <0.05.the possibility that Ang1-MSCs enhance angiogenesis
through differentiation into endothelial cells, we found
cells that coexpressed CD31 and GFP (Figure 9), revealing
that Ang1-MSCs were able to differentiate into endothe-
lial cells. These observations suggest that the Ang1-
MSC-induced improvements in wound healing occurred
by enhanced angiogenesis, and that this enhanced angio-
genesis resulted from differentiation of MSCs into endo-
thelial cells.richrome-stained images at day 21 after treatment. Angiopoietin-1
ounds showed an arranged collagen network, indicating more
. (B) Ang1-MSC-treated wounds display much denser collagen than
cells (MSCs), recombinant adenovirus encoding angiopoietin-1
Figure 7 Engraftments of angiopoietin-1 gene-modified bone marrow mesenchymal stem cells into wounded skin and angiopoietin-1
expression. (A) Confocal microscopy images showing green fluorescent protein-positive (GFP+) mesenchymal stem cells (MSCs; green) in
angiopoietin-1 gene-modified bone marrow mesenchymal stem cell (Ang1-MSC)-treated wounds at day 21 after transplantation. Nuclei were
stained with Hoechst (blue). Scale bar = 50 μm. (B) Confocal microscopy images showing immunostaining for angiopoietin-1 (Ang1; red) in
GFP-labeled MSCs (green) at day 7 after transplantation. Nuclei were stained with Hoechst (blue). After merging, the cells of coexpressing GFP
and Ang1 are indicated (yellow). Scale bar = 50 μm. Ad-Ang1, recombinant adenovirus encoding angiopoietin-1.
Figure 8 Angiopoietin-1 gene-modified bone marrow mesenchymal stem cells promote angiogenesis. (A) Representative images
showing CD31 staining (yellow) on day 7 after wound treatment with angiopoietin-1 gene-modified bone marrow mesenchymal stem cells
(Ang1-MSCs), recombinant adenovirus encoding angiopoietin-1 (Ad-Ang1), mesenchymal stem cells (MSCs), and sham. Scale bar = 50 μm.
(B) Capillary density was increased in Ang1-MSC-treated wounds compared with MSC-treated, Ad-Ang1-treated, and sham-treated wounds.
Analysis of variance versus MSCs, Ad-Ang1 or sham, *P <0.05.
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Figure 9 Immunofluorescent staining for endothelial protein CD31. Representative confocal images showing CD31 (red) and green
fluorescent protein (GFP) staining at day 14 in a wound after treatment with recombinant adenovirus encoding angiopoietin-1 (Ad-Ang1),
mesenchymal stem cells (MSCs) and angiopoietin-1 gene-modified bone marrow mesenchymal stem cells (Ang1-MSCs). Nuclei were stained blue
with Hoechst (blue). GFP and CD31 double-positive cells (yellow) were only found in Ang1-MSC-treated wounds. Scale bar = 50 μm.
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Chronic skin wounds such as diabetic ulcers, radiation-
induced injury-impaired wounds, and malnutrition-
associated wounds are difficult to heal, and remain a
great challenge to clinicians [27,28]. Little improvement
has been made in the enhancing wound healing in the
past few decades. Innovative treatments to enhance the
chronic wound healing process are therefore needed.
Cell therapy has been applied to chronic wounds for
many years. However, in previous studies, transplan-
tation of some cells such as allogeneic fibroblasts just
resulted in tissue repair, leading to increased inflamma-
tion and scar formation [29]. In this study, by tracing
GFP expression, we observed transplanted Ang1-MSCs
localized into the skin epithelium and dermis, and the
GFP+ MSCs were still present up to day 21 after trans-
plantation. Ang1-MSCs promoted epithelial maturation
and collagen deposition, and significantly increased the
number of regenerating appendage structures comparedwith MSC-treated, Ad-Ang1-treated, or sham-treated
wounds. These results suggest that engrafted Ang1-MSCs
in the wound accelerate epidermal and dermal regene-
ration rather than forming scar tissue.
Because of rapid degradation and drying out in the
open wound, the topical application of various cell factors
to stimulate chronic wound healing has been explored,
but without significant advancements. Considerable atten-
tion has thus been paid to cell and gene therapies to treat
chronic wounds. The combination of cell and gene ther-
apies has been used to introduce various exogenous genes
into chronic wounds in animal models, with the aim of
overcoming the limitations of direct application of recom-
binant cell factors. In this study, Ang1 gene-modified
MSCs were established by recombinant adenovirus in-
fection and locally transplanted to the wound site. In our
experiments, the efficiency of wound healing and skin re-
generation was in the following order: Ang1-MSCs >
MSCs or Ad-Ang1 > sham. Our results thus showed that
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more effective than the transplantation of either MSCs
alone or Ad-Ang1 treatment alone. The combination of
MSCs and Ang1 demonstrated synergistic effects on pro-
moting wound repair, resulting from the effects of MSCs
and the additional benefit of Ang1 expression. Ang1 pro-
duced by MSCs plays a role in coordinating and regulating
cellular processes and wound healing.
Neovascularization is a crucial step in wound-healing
process. In this study, we demonstrated that Ang1-MSC-
treated wounds are surrounded by a denser capillary net-
work compared with the other groups, suggesting that
Ang1-MSCs promoted angiogenesis in the regenerated
dermis compared with MSCs, Ad-Ang1 or sham. Our re-
sults also demonstrated that the engrafted GFP+ MSCs in
the wound express CD31 subunit, and these GFP+CD31+
MSCs remained in the wound at day 21 after transplan-
tation. These results suggest that Ang1-MSCs can thus
differentiate into vascular endothelial cells in wounds,
which may be partially responsible for the role of Ang1-
MSCs in enhancing angiogenesis.
Conclusion
This study demonstrated the efficacy of cell-based gene
therapy with Ang1-MSCs on enhancing wound healing
in rats by promoting epidermal and dermal regeneration,
and angiogenesis. Ang1-MSCs administration may thus
represent a novel therapeutic approach to clinically ex-
plore further improvements in cutaneous wound therapy.
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